GLIKNIK INC. is a biopharmaceutical company that focuses on developing treatments for patients with cancer and immune disorders. Established in 2007 and headquartered in Baltimore, Maryland, the company harnesses innovation to empower immune responses and combat cancer with advanced peptide, immunoglobulin, and monoclonal antibody therapies.
The company's Immunomodulator Platform is centered around off-the-shelf peptide drugs that boost CD4, CD8, and antibody immune responses against cancer. It also has a Stradomer Platform that creates drugs designed to replicate the effectiveness of pooled human intravenous immunoglobulin, and a Stradobody Platform that generates compounds akin to monoclonal antibodies for targeting and eliminating tumor cells.
GLIKNIK INC. received a $2.84M Venture Round investment on 03 September 2013.
With its focus on biotechnology and healthcare, the company is positioned to make a significant impact in the field of cancer treatment and immune system disorders.
